Maine revamps funding formula

Vesely, Rebecca
June 2009
Modern Healthcare;6/15/2009, Vol. 39 Issue 24, p14
Trade Publication
The article offers information on Medicare laws in Maine as of June 15, 2009. Maine decided to abandon its offset payment for Dirigo Health, while it expanded its certificate-of-need rules (CON) to apply to new medical equipment cost assessment. Another two laws required hospitals in the state to prevent the spread of methicillin-resistant Staphylococcus aureus infections.


Related Articles

  • Intensive MRSA control programme cost saving in Sweden.  // PharmacoEconomics & Outcomes News;11/6/2004, Issue 465, p5 

    Reports on the savings achieved from meticillin-resistant Staphylococcus aureus infection control programme in a Swedish hospital. Cost of the programme; Benefit of the programme to the hospital.

  • News in brief . . .  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p10 

    Discusses research being done on costs associated with staphylococcus aureus poststernotomy mediastinitis following sternotomy for cardiac surgery in New Zealand. Reference to a study by A. Upton et al published in the February 25, 2005 issue of the "New Zealand Medical Journal"; Outcome of the...

  • Substantial cost burden of inpatient staphylococcal infection.  // PharmacoEconomics & Outcomes News;9/24/2005, Issue 487, p8 

    Discusses research being done on Staphylococcus aureus infections on hospitals in the U.S. Reference to a study conducted by G. A. Noskin, R. J. Rubin, J. J. Schentag, J. Kluytmans, E. C. Hedblom, M. Smulders, E. Lapetina and E. Gemmen, published in the August 2005 issue of the "Archives of...

  • Inappropriate therapy for MRSA costly, potentially deadly, problem.  // PharmacoEconomics & Outcomes News;9/6/2008, Issue 561, p5 

    The article focuses on a study which indicate that inappropriate therapy for people with methicillin-resistant Staphylococcus aureus (MRSA) infections leads to prolonged hospitalization and increased costs. It references studies published in the August 2008 issue of the periodical "Critical Care...

  • Potential for high clinical, cost burden with MRSA.  // PharmacoEconomics & Outcomes News;10/9/2004, Issue 463, p10 

    Discusses research being done on the clinical and economic implications of meticillin-susceptible and -resistant Staphylococcus aureus infections. Reference to a study by B. J. Koop et al published in the September 2004 issue of "Annals of Pharmacotherapy"; Hospital and antibacterial-related...

  • Septicaemia due to S aureus costly in ESRD.  // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p6 

    Presents information on a study which focused on the cost of hospitalization of patients with end-stage renal disease who develop septicemia caused by Staphylococcus aureus. Complications of the hospitalization costs; Length of hospital stay for the index admission on the average; Percentage of...

  • Money matters in infection control policy. Traynor, Kate // American Journal of Health-System Pharmacy;8/15/2005, Vol. 62 Issue 16, p1650 

    Reports on the creation of policies to successfully tackle the problem of antimicrobial resistance in the U.S. Necessity to gain understanding of the economics of resistance and the creation of a good clinical care program; Explanation of how the medical center’s administrators came to...

  • Staphylococcus aureus bacteraemias: time to act. Collignon, Peter J.; Cruickshank, Marilyn // Medical Journal of Australia;10/5/2009, Vol. 191 Issue 7, p363 

    The article discusses various reports published within the issue, including one by J. D. Turnidge and colleagues on how Staphylococcal aureus bacteraemia (SAB) infections occur and another by C. Dendle and colleagues on how SAB infections can serve as a clinical quality indicator for all hospitals.

  • Rochester General: Aiming for "zero defects". G. A. // Materials Management in Health Care;Aug2009, Vol. 18 Issue 8, p23 

    The article reports on the launching of a Methicillin-resistant Staphylococcus aureus (MRSA)-prevention program by Rochester General Hospital in New York on February 2007. The hospital's primary objective is to wipe out all infections nationwide. The hospital's MRSA-prevention program uses the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics